Research programme: anti-SARS-CoV-2 monoclonal antibodies - SpikImm
Alternative Names: Research programme: anti-COVID-2019 monoclonal antibodies - SpikImmLatest Information Update: 29 Sep 2021
At a glance
- Originator Institut Pasteur
- Developer SpikImm
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections